Study Summary
This trial is testing the safety and side effects of two different treatments for melanoma that has spread to nearby tissue or lymph nodes.
- Locally Advanced Melanoma
- Metastatic Melanoma
- Pathologic Stage III Cutaneous Melanoma
- Stage IIIB Cutaneous Melanoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 2 Secondary · Reporting Duration: Up to 2 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Treatment (pembrolizumab, lifileucel)
1 of 1
Experimental Treatment
15 Total Participants · 1 Treatment Group
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 75 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has Pembrolizumab obtained clearance from the FDA?
"The safety of Pembrolizumab is estimated to be a 1, as this Phase 1 trial contains limited information on its efficacy and safety." - Anonymous Online Contributor
Are there any previous data sets that have evaluated the efficacy of Pembrolizumab?
"At present, 1817 clinical trials are researching Pembrolizumab. Of those active investigations, 281 have entered Phase 3 testing. While the majority of these studies take place in Philadelphia, Pennsylvania, globally 63417 sites are running research with this medication." - Anonymous Online Contributor
What is the current cohort size for this medical experiment?
"Affirmative. Clinicaltrials.gov attests to the fact that this clinical trial is actively seeking participants, having been initially posted on July 1st 2022 and most recently updated on October 24th 2022. The study requires 15 patients from one centre." - Anonymous Online Contributor
Is the age restriction of this trial under 55 years old?
"To participate in this trial, applicants must be over the age of consent and below 75. There are 395 studies available to individuals under 18 years old and 2389 trials for those above 65." - Anonymous Online Contributor
In what ways has Pembrolizumab been found to be beneficial for patients?
"Pembrolizumab is typically prescribed for lymphoma and non-Hodgkin's disease. Additionally, this medication may be beneficial in the treatment of malignant melanomas, recurrent cervical cancer, and leukemia." - Anonymous Online Contributor
Would it be feasible to partake in this research study at present?
"Right, the information available on clinicaltrials.gov attests that this trial is actively recruiting candidates. The research was initially made public on July 1st 2022 and has been edited as recently as October 24th 2022. A total of 15 participants need to be enrolled at a single site for the study's completion." - Anonymous Online Contributor
Are there any criteria for participating in this medical experiment?
"This medical trial is enrolling 15 participants aged 18-75 with cutaneous melanoma. In order to be eligible, no prior therapies are permitted and all applicants must have received pathology confirmation of their condition in the 28 days before commencing treatment. Additionally, those with BRAF V600E/K mutations and past or concurrent malignancies that don't interfere the safety evaluations can qualify for entry. Furthermore, it's important that patients possess an ECOG performance score of 0-1 as well as estimated life expectancy greater than three months; they must also demonstrate measurable disease across primary sites (20mm CXR scan minimum) plus a" - Anonymous Online Contributor